This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Food Allergy Vaccine (Sanofi/Immune Design)
Drug Names(s): Food Allergy Vaccine (Sanofi/Immune Design)
Description: The vaccine being developed by Sanofi and Immune Design's GLAAS platform is looking to treat food allergy. Immune Design's GLAAS platform works in vivo and is based on a small synthetic molecule called GLA, or glucopyranosyl lipid adjuvant. GLA selectively binds to the TLR4 receptor and causes potent activation of dendritic cells (DCs) leading to the production of cytokines and chemokines that drive a Th1-type immune response.
Immune Design and Sanofi
In August 2014, Sanofi and Immune Design announced that they have entered into a licensing agreement for use of Immune Design's GLAAS discovery platform to develop therapeutic agents to treat a selected food allergy.
Under terms of the agreement, Immune Design has granted Sanofi an exclusive license to discover, develop and commercialize products to treat a selected food allergy. The company has received an undisclosed upfront payment and will be eligible to receive development and commercialization milestones totaling US $168 million, as well as tiered royalties on sales of approved products.
Partners: Immune Design Corporation
Food Allergy Vaccine (Sanofi/Immune Design) News
Additional information available to subscribers only: